Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Randomized, double-blinded, placebo-controlled trial comparing oral anticoagulation with
placebo for community-dwelling patients with symptomatic COVID-19 infection and risk factors
for thrombosis.
Phase:
Phase 4
Details
Lead Sponsor:
Brazilian Clinical Research Institute
Collaborators:
Beneficência Portuguesa de São Paulo Brazilian Research In Intensive Care Network Hospital Alemão Oswaldo Cruz Hospital do Coracao Hospital Israelita Albert Einstein Hospital Moinhos de Vento Hospital Sirio-Libanes